Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

计划入组 210 人 · 首次发布于 2026 年 9 月 14 日

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

计划入组 2,500 人 · 首次发布于 2026 年 5 月 4 日

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

计划入组 400 人 · 首次发布于 2026 年 1 月 22 日

BioChaperone Glucagon

BioChaperone Pramlintide Insulin

Cagrilintide/Semaglutide

Carisma Therapeutics

United States

Adocia Files Patent for AdoXLong Platform to Extend Peptide Therapy Duration to Monthly Injections

Adocia Secures €9.7 Million Private Placement to Advance Diabetes and Obesity Pipeline Through Q2 2026

Adocia to Host Virtual KOL Event Reviewing Phase 3 Results of Ultra-Rapid Insulin BioChaperone Lispro in Type 2 Diabetes